Canton Strategic Holdings, Inc.

Canton Strategic Holdings, Inc. operates across two distinct business areas: blockchain infrastructure and pharmaceutical development. The company leverages Canton Coin and the Canton network to facilitate institutional blockchain adoption and support the digitization of financial markets. On the pharmaceutical side, the company conducts research and development of targeted drug formulations, including GV104, a buccal film technology that has completed Phase 1 trials for treating respiratory and nervous system depression in military personnel and chemical incident responders, and GV023, an oral formulation of infliximab designed to address treatment limitations associated with intravenous infusion regimens.

The company maintains a minimal operational footprint with two full-time employees and is headquartered in Red Bank, New Jersey. Canton Strategic Holdings was incorporated in Delaware and trades on the Nasdaq. The company was formerly known as Tharimmune, Inc. before rebranding to its current name in February 2026, reflecting its strategic pivot toward blockchain-related initiatives alongside its pharmaceutical development efforts.